| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Butamirate targets the cough reflex center in the brainstem. It works by acting centrally through the receptors in the brainstem. Unlike codeine, it is not related to the opioids and does not have opioid-like effects. Butamirate's mechanism involves the suppression of the cough reflex at the central level, reducing the urge to cough. Its non-opioid mechanism makes it a safer alternative for cough suppression.
|
|---|---|
| ln Vitro |
In vitro, butamirate is a cough suppressant that works by acting centrally through the receptors in the brainstem. It is a non-opioid drug that does not have opioid-like effects. In cell-based assays, butamirate treatment results in suppression of neuronal activity in the cough reflex center. The compound's effects on cough reflex are assessed using electrophysiological methods or in vitro models of cough. These studies confirm the compound's mechanism as a centrally acting antitussive.
|
| ln Vivo |
In vivo, butamirate is used orally to treat irritable (non-productive) cough. It is used to treat respiratory tract infections and is available in syrup, drop, or tablet form. Butamirate is a non-opioid drug that acts on the cough reflex center in the brainstem. Its efficacy in reducing cough has been demonstrated in clinical studies. Butamirate is available as an over-the-counter or prescription medication in many countries.
|
| Enzyme Assay |
In vitro receptor binding assays for butamirate are not well-documented, as the compound's mechanism involves action on the cough reflex center rather than specific receptor binding. Its effects on neuronal activity can be assessed using electrophysiological methods in brainstem preparations. The compound's non-opioid mechanism is confirmed by the lack of binding to opioid receptors. These assays confirm the compound's mechanism as a centrally acting antitussive.
|
| Cell Assay |
In vitro cell-based assays for butamirate are not typically performed, as the compound's mechanism involves action on the cough reflex center in the brainstem. However, its effects on neuronal cells can be assessed using electrophysiological methods. The compound's cytotoxicity is assessed using standard cell viability assays. These assays confirm the compound's safety profile.
|
| Animal Protocol |
In vivo animal experiments for butamirate have been conducted in animal models of cough. Animals are treated with butamirate, and cough frequency and intensity are assessed. The compound's efficacy in reducing cough has been demonstrated in preclinical studies. Pharmacokinetic studies are conducted to determine the compound's absorption, distribution, metabolism, and excretion. Comprehensive in vivo studies are available from clinical development.
|
| ADME/Pharmacokinetics |
Butamirate is absorbed after oral administration and is metabolized in the liver. It has a molecular weight of 307.43 g/mol. The compound's half-life, bioavailability, and excretion profile have been characterized in clinical studies. Butamirate is available as a cough suppressant medication in many countries.
|
| Toxicity/Toxicokinetics |
The toxicity of butamirate is low at therapeutic doses. Common side effects include gastrointestinal disturbances, headache, and dizziness. The compound is not related to the opioids and does not have opioid-like side effects. Butamirate is available as an over-the-counter or prescription medication in many countries.
|
| Additional Infomation |
Butyramide is an alkylbenzene.
Butamirate is a cough suppressant drug used orally to treat irritable (non-productive) cough. It is a non-opioid drug that acts on the cough reflex center in the brainstem. Butamirate is used to treat respiratory tract infections and is available in syrup, drop, or tablet form. It has a molecular formula of C₁₈H₂₉NO₃. Butamirate is available as a cough suppressant medication. |
| Molecular Formula |
C18H29NO3
|
|---|---|
| Molecular Weight |
307.434
|
| Exact Mass |
307.215
|
| CAS # |
18109-80-3
|
| Related CAS # |
18109-80-3;18109-81-4 (citrate);
|
| PubChem CID |
28892
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.007g/cm3
|
| Boiling Point |
394.4ºC at 760mmHg
|
| Flash Point |
192.3ºC
|
| Vapour Pressure |
1.99E-06mmHg at 25°C
|
| Index of Refraction |
1.497
|
| LogP |
3.081
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
12
|
| Heavy Atom Count |
22
|
| Complexity |
286
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCN(CCOCCOC(C(C1C=CC=CC=1)CC)=O)CC
|
| InChi Key |
DDVUMDPCZWBYRA-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C18H29NO3/c1-4-17(16-10-8-7-9-11-16)18(20)22-15-14-21-13-12-19(5-2)6-3/h7-11,17H,4-6,12-15H2,1-3H3
|
| Chemical Name |
2-[2-(diethylamino)ethoxy]ethyl 2-phenylbutanoate
|
| Synonyms |
Abbott 36581HH-197,Abbott-36581HH 197,Sincodex, Sincodin,Acodeen,Sincodeen, Sincodix,Butamyrate citrate, Sinecod
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2528 mL | 16.2639 mL | 32.5277 mL | |
| 5 mM | 0.6506 mL | 3.2528 mL | 6.5055 mL | |
| 10 mM | 0.3253 mL | 1.6264 mL | 3.2528 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
